We will review small molecule inhibitors directly targeting b-catenin/Tcf4 interactions.
What is it about?
Small molecule inhibitors targeting b-catenin/Tcf4 interactions
Why is it important?
Small molecules that block the interactions between b-catenin and Tcf4, a downstream stage of activation of the Wnt/b-catenin signaling pathway, could efficiently cut off this signal transduction and thereby act as a novel class of anticancer drugs. This paper reviews the currently reported inhibitors that target b-catenin/Tcf4 interactions, focusing on the discovery approaches taken in the design of these inhibitors and their bioactivities. A brief perspective is then shared on the future discovery and development of this class of inhibitors.
The following have contributed to this page: Jing An and Guanqun Li